Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inupadenant Monotherapy and Combination in Advanced Cancers
NCT03873883Phase 1Completed
- Sponsor
- iTeos Therapeutics
- Start
- Feb 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of inupadenant in solid tumor, melanoma, castration-resistant prostate cancer (CRPC) and 4 more (6 arms), sponsored by iTeos Therapeutics. Primary endpoints: Incidence of Dose-Limiting Toxicities and Incidence and severity of Adverse Events up to 30 months. Started Feb 2019; status: completed.
02
Drugs
inupadenant
03
Conditions
solid tumormelanomacastration-resistant prostate cancer (CRPC)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03873883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03873883.